Kuang Jie, Jin Zhijian, Chen Lingxie, Zhao Qiwu, Huang Haiyan, Liu Zhuoran, Yang Weiping, Feng Haoran, Yang Zheyu, Díez Juan J, Pusztaszeri Marc, Kim Jung Min, Bonati Elena, Cheng Xi, Yan Jiqi, Qiu Weihua
Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Shanghai Institute of Digestive Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Ann Transl Med. 2022 Feb;10(4):193. doi: 10.21037/atm-22-10.
Low levels of vitamin D and altered local vitamin D metabolism have been associated with the prevalence and aggressiveness of several cancers. However, the effect of vitamin D on papillary thyroid cancer (PTC) is controversial. This study aimed to evaluate the impact of preoperative serum vitamin D levels and local vitamin D metabolism on the clinicopathologic characteristics and prognosis of PTC.
In total, 1,578 patients with PTC and 128 patients with benign thyroid diseases were included. Clinical and pathologic data were analyzed to evaluate the role of vitamin D as a risk factor and prognostic marker in PTC. Moreover, a tissue microarray was used to investigate the role of local vitamin D metabolism in PTC progression.
Participants with PTC were younger compared to those with benign disease. No significant differences in 25-hydroxy vitamin D [25(OH)D] levels were observed between benign and malignant cases. Among patients with PTC, analyses of prognostic features revealed that decreased 25(OH)D levels were not overtly associated with poor prognosis in PTC. Additionally, local vitamin D metabolism was not associated with the aggressiveness of PTC.
Serum 25(OH)D determination may not contribute to risk assessment workup of thyroid nodules. Moreover, decreased preoperative serum vitamin D and local vitamin D metabolism were not associated with poor prognosis of PTC.
维生素D水平低下及局部维生素D代谢改变与多种癌症的患病率和侵袭性相关。然而，维生素D对甲状腺乳头状癌（PTC）的影响存在争议。本研究旨在评估术前血清维生素D水平和局部维生素D代谢对PTC临床病理特征及预后的影响。
共纳入1578例PTC患者和128例甲状腺良性疾病患者。分析临床和病理数据，以评估维生素D作为PTC风险因素和预后标志物的作用。此外，使用组织芯片研究局部维生素D代谢在PTC进展中的作用。
与良性疾病患者相比，PTC患者更年轻。良性和恶性病例之间未观察到25-羟基维生素D[25(OH)D]水平的显著差异。在PTC患者中，预后特征分析显示，25(OH)D水平降低与PTC预后不良无明显关联。此外，局部维生素D代谢与PTC的侵袭性无关。
血清25(OH)D测定可能无助于甲状腺结节的风险评估检查。此外，术前血清维生素D降低和局部维生素D代谢与PTC预后不良无关。
